Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting

Summary

The FDA is holding a PDUFA VIII meeting to gather stakeholder input on regulatory priorities for fiscal years 2028–2032, with focus areas including rare disease reform, CMC risk management, and reshoring of US trials.